The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1. [PDF]
Shoumariyeh K +14 more
europepmc +1 more source
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time? [PDF]
Atluri H, Abaza Y, Altman JK.
europepmc +1 more source
Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis. [PDF]
Wang X +5 more
europepmc +1 more source
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 [PDF]
Uy, Geoffrey L., Westervelt, Peter
core +1 more source
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. [PDF]
Oh HC, Han Y, Chang Y, Kim HH.
europepmc +1 more source
A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis. [PDF]
Sawa M +17 more
europepmc +1 more source
Hsp70 Peptides Induce TREM-1-Dependent and TREM-1-Independent Activation of Cytotoxic Lymphocytes. [PDF]
Yurkina DM +8 more
europepmc +1 more source
Survival Outcome of AML Patients with and without TKD Mutations
Sadaf, Shahab +9 more
openaire +3 more sources
Parvovirus B19, Somatic Gene Mutations, and Hematologic Malignancy Subtypes: An Analytical Study. [PDF]
Khudhair AM +3 more
europepmc +1 more source

